Portola Pharmaceuticals Profit Margin

Portola Pharmaceuticals posts a profit margin of -232.73% as of March 2020. That compares with -618.45% in the prior-year period — up 62.4% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Portola Pharmaceuticals's profit margin was -618.45%. The latest reading is -232.73% — a 62.4% year-over-year increase (period ending March 2020). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Portola Pharmaceuticals's -232.73% is lower that level. That is roughly 1775.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Portola Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -232.73% as of March 2020; use YoY and peer views to separate noise from signal.

Context for PTLA's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Portola Pharmaceuticals's other metric pages and overview cover the third.